Semax Dosing Protocols in Preclinical Models: What the Research Shows

Introduction

Semax (Met-Glu-His-Phe-Pro-Gly-Pro), a synthetic heptapeptide analogue of the ACTH(4–7) fragment with a C-terminal Pro-Gly-Pro extension, has accumulated a substantial body of preclinical research since its development at the Institute of Molecular Genetics of the Russian Academy of Sciences. Used clinically in Russia for ischemic stroke and cognitive disorders, Semax has become an increasingly common subject in Western peptide research laboratories — yet the question of how to structure dosing protocols for specific experimental endpoints is rarely addressed comprehensively in the literature.

This article synthesizes the dosing parameters reported across the Semax preclinical literature, organized by research application, to provide laboratory researchers with a practical reference for protocol design. All content is for research and educational purposes only.

Pharmacokinetic Considerations That Inform Dosing

Before examining specific dose ranges, understanding Semax's pharmacokinetic profile is essential for protocol design. The Pro-Gly-Pro C-terminal extension that distinguishes Semax from the parent ACTH(4–7) fragment confers significantly enhanced resistance to enzymatic degradation, extending the peptide's half-life in biological matrices compared to unmodified melanocortin fragments [1].

Route of administration profoundly affects both bioavailability and the balance of nootropic versus anxiolytic effects. A 2020 study by Vasileva et al. directly compared intranasal and intraperitoneal Semax administration in BALB/c and C57BL/6 mice, finding that the route of administration shifted the predominance of effects: intranasal delivery produced more pronounced nootropic effects, while intraperitoneal administration showed a stronger anxiolytic profile in anxiety-prone BALB/c mice [2]. This finding has direct implications for protocol design — researchers targeting cognitive endpoints should consider intranasal delivery, while those studying anxiety-circuit modulation may prefer systemic routes.

Species and strain differences also influence effective dose ranges. BALB/c mice, which exhibit higher baseline anxiety, show different dose-response relationships than C57BL/6 mice for both cognitive and anxiolytic endpoints [2]. Rat models, which dominate the ischemia and neuroprotection literature, use weight-based dosing that does not translate directly to mouse protocols.

Dose Ranges by Research Application

Cognitive Enhancement and Working Memory

The cognitive enhancement literature for Semax centers on its ability to upregulate BDNF and activate dopaminergic and serotonergic systems. Eremin et al. (2005) demonstrated that Semax at 0.6 mg/kg intraperitoneal in rats produced significant increases in dopamine and serotonin turnover in the frontal cortex and hippocampus — neurochemical changes consistent with enhanced attentional and working memory performance [3].

For behavioral cognitive endpoints in rodent models, the literature most commonly reports dose ranges of 0.1–1.0 mg/kg administered intraperitoneally or intranasally, with the lower end of this range (0.1–0.3 mg/kg) appearing sufficient for BDNF-mediated effects and the higher end (0.5–1.0 mg/kg) used in models of cognitive impairment where a stronger intervention is needed [4].

Timing relative to behavioral testing matters significantly. Semax's effects on gene expression — particularly BDNF, NGF, and VEGF transcription — peak at approximately 3–6 hours post-administration in rodent brain tissue [5]. Protocols targeting neurotrophin-mediated outcomes should account for this window when scheduling behavioral assessments.

Neuroprotection and Ischemia Models

The most extensively characterized Semax dosing data comes from ischemia-reperfusion models, where Semax has been studied as a potential neuroprotective agent. The standard dose used across multiple rat middle cerebral artery occlusion (MCAO) studies is 10 μg/100g body weight (0.1 mg/kg) administered intraperitoneally, typically beginning at the time of reperfusion or within 1–6 hours of ischemic onset [6].

Dmitrieva et al. (2010) used this dose range to demonstrate that Semax promotes earlier upregulation of BDNF and VEGF transcription following cerebral ischemia, with effects on neurotrophin gene expression detectable within 3 hours of administration [7]. Subsequent proteomic studies confirmed that this dose range produces measurable changes in the expression of proteins involved in inflammation, oxidative stress, and synaptic function [8].

For chronic neuroprotection protocols, Medvedeva et al. (2016) examined Semax effects on growth factor mRNA levels at 3 days post-ischemia, finding sustained upregulation of BDNF, FGF2, IGF2, and ZFP9 at doses consistent with the acute literature [9]. This suggests that the 0.1 mg/kg range maintains biological activity across both acute and subacute timeframes in ischemia models.

| Model Type | Typical Dose | Route | Timing | Key Endpoints | |---|---|---|---|---| | Cognitive enhancement (rodent) | 0.1–1.0 mg/kg | IP or intranasal | 30–60 min pre-test | BDNF, working memory, exploration | | Ischemia/neuroprotection (rat) | 0.1 mg/kg (10 μg/100g) | IP | At reperfusion or within 6h | Infarct volume, BDNF, neurological score | | Anxiety-cognition (mouse) | 0.1–0.5 mg/kg | IP or intranasal | 30 min pre-test | EPM, open field, novel object recognition | | Chronic cognitive impairment | 0.1–0.3 mg/kg | IP | Daily × 7–14 days | Morris water maze, gene expression | | Dopamine/serotonin neurochemistry | 0.6 mg/kg | IP | Single acute dose | Monoamine turnover, HPLC |

Anxiety and Stress Models

While Semax is primarily characterized as a nootropic, its effects on anxiety-related behavior are documented and route-dependent. In the elevated plus maze and open field test, Semax at 0.1–0.3 mg/kg administered intraperitoneally produces measurable reductions in anxiety-like behavior in BALB/c mice, though the effect magnitude is smaller than that observed with Selank at comparable doses [2].

For protocols specifically targeting the anxiety-cognition interface — studying how stress impairs working memory, for example — Semax's profile of simultaneously reducing anxiety-like behavior while enhancing cognitive performance makes it a useful single-compound intervention that avoids the cognitive impairment associated with benzodiazepine reference compounds.

Reconstitution and Storage for Laboratory Use

Semax is supplied as a lyophilized powder and requires reconstitution before use in experimental protocols. Standard laboratory practice uses bacteriostatic water (0.9% benzyl alcohol in sterile water) as the reconstitution vehicle, which provides antimicrobial preservation and extends the usability window of the reconstituted solution.

For a 5mg vial, adding 1.0 mL of bacteriostatic water yields a stock concentration of 5 mg/mL (5000 μg/mL), which can then be diluted to working concentrations appropriate for the target dose range. For the 0.1 mg/kg dose in a 250g rat, a working concentration of 0.1 mg/mL requires a 50-fold dilution of the 5 mg/mL stock.

Reconstituted Semax solutions should be stored at 2–8°C and used within 28 days. Avoid repeated freeze-thaw cycles, which can degrade peptide integrity. For long-term storage of unused lyophilized material, -20°C is appropriate.

Considerations for Protocol Reproducibility

Several factors in the Semax literature affect reproducibility and should be explicitly controlled in experimental design:

Vendor and purity: Semax purity varies significantly across suppliers. The neurotrophin gene expression effects documented in the literature were produced with high-purity material (>98% by HPLC). Lower-purity preparations may contain degradation products that confound results or reduce effective dose.

Administration timing consistency: Given Semax's effects on gene expression timing (peak at 3–6 hours), inconsistent administration timing relative to behavioral testing or tissue collection will introduce variability in both behavioral and molecular endpoints.

Baseline anxiety stratification: In mouse studies, pre-screening animals in the open field test and stratifying by baseline anxiety level before group assignment substantially reduces within-group variance, particularly for BALB/c strains where anxiety-related phenotype variability is high.

Conclusion

Semax has a well-characterized dose range across its primary research applications, with the 0.1–1.0 mg/kg range covering most cognitive and neuroprotective endpoints and the 0.1 mg/kg intraperitoneal dose being the most consistently replicated in ischemia models. Route of administration is a critical variable that shifts the balance between nootropic and anxiolytic effects, and researchers should select routes based on their primary endpoint. High-purity material and consistent administration timing are essential for reproducible results.

All research involving Semax is conducted for research purposes only within controlled laboratory environments. This article is for scientific and educational reference only.

References

1. Mjasoedov, N.F., et al. (2014). The Potential of the Peptide Drug Semax and Its Derivative for the Treatment of CNS Pathologies. Frontiers in Pharmacology. https://pdfs.semanticscholar.org/7ccf/4ad4a72165c8aa83be280ddb598951c0f9bc.pdf
2. Vasileva, E.V., et al. (2020). Predominance of Nootropic or Anxiolytic Effects of Selank, Semax, and Noopept Peptides Depending on the Route of Administration to BALB/c and С57BL/6 Mice. Neurochemical Journal, 14(3), 248–255. https://link.springer.com/article/10.1134/S1819712420030113
3. Eremin, K.O., et al. (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12), 1493–1500.
4. Filippenkov, I.B., et al. (2021). Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4–7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia–Reperfusion. International Journal of Molecular Sciences, 22(12), 6179. https://www.mdpi.com/1422-0067/22/12/6179
5. Dmitrieva, V.G., et al. (2010). Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cellular and Molecular Neurobiology, 30(1), 71–79.
6. PMC (2020). Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) in a Rat Ischemia Model. PMC7350263. https://pmc.ncbi.nlm.nih.gov/articles/PMC7350263/
7. Dmitrieva, V.G., et al. (2010). Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cellular and Molecular Neurobiology, 30(1), 71–79. https://link.springer.com/article/10.1007/s10571-009-9432-0
8. Sudarkina, O.Y., et al. (2021). Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4–7)PGP Peptide (Semax). IJMS, 22(12), 6179.
9. Medvedeva, E.V., et al. (2016). Semax-induced changes in growth factor mRNA levels in the rat brain on the third day after ischemia. International Journal of Peptide Research and Therapeutics, 22(3), 351–357.

See Also: Semax Research Overview · Semax BDNF Neuroprotection · Semax vs Selank Comparison